News Lilly invests another $3bn in its manufacturing network Lilly will spend $3 billion on a recently acquired Wisconsin plant for injectable medicines, including diabetes and obesity drugs.
News Mounjaro cleared for NHS use, but patients may have to wait Many patients can expect a long wait for access to Eli Lilly's obesity shot Mounjaro, even though it has been recommended for routine NHS use by NICE
News Zepbound tops Wegovy in first head-to-head weight-loss trial Eli Lilly is playing catch-up to Novo Nordisk in the fast-growing obesity therapy sector but has new data that could tip the balance in its favour.
News Amgen's big reveal of obesity data falls a little flat Top-line phase 2 results with Amgen's MariTide drug for obesity are finally in, but don't seem to have lived up to investor expectations
News Biden ramps up Medicare coverage of obesity drugs Outgoing US President Joe Biden has proposed a dramatic expansion of Medicare coverage of obesity drugs, but will the plan see the light of day?
News Amgen plays down safety concern with obesity candidate Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone mineral density that could undermine its ability to compete in t
News Lilly's 'triple G' retatrutide aces crucial obesity trial Lilly's retatrutide achieved weight loss of more than 30% at two years in a new trial, firming up its credentials as a next-generation obesity drug.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
